Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Inhibikase Therapeutics Inc

IKT
Current price
1.46 USD +0.095 USD (+6.99%)
Last closed 1.36 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 8 370 722 USD
Yield for 12 month -48.40 %
1Y
3Y
5Y
10Y
15Y
IKT
21.11.2021 - 28.11.2021

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia. Address: 3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

15.5 USD

P/E ratio

Dividend Yield

Current Year

+260 500 USD

Last Year

+123 440 USD

Current Quarter

Last Quarter

+1 USD

Current Year

+83 102 USD

Last Year

+116 717 USD

Current Quarter

-6 568 USD

Last Quarter

-6 567 USD

Key Figures IKT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -19 978 280 USD
Operating Margin TTM -10285.34 %
PE Ratio
Return On Assets TTM -64.23 %
PEG Ratio
Return On Equity TTM -119.64 %
Wall Street Target Price 15.5 USD
Revenue TTM 195 980 USD
Book Value 1.05 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100 %
Dividend Yield
Gross Profit TTM -8 258 499 USD
Earnings per share -3.32 USD
Diluted Eps TTM -3.32 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics IKT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IKT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:6
Payout Ratio
Last Split Date 30.06.2023
Dividend Date

Stock Valuation IKT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.748
Price Sales TTM 55.2066
Enterprise Value EBITDA -0.0688
Price Book MRQ 1.31

Financials IKT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators IKT

For 52 weeks

0.79 USD 3.48 USD
50 Day MA 1.56 USD
Shares Short Prior Month 121 292
200 Day MA 1.62 USD
Short Ratio 1.66
Shares Short 93 489
Short Percent 1.46 %

Dynamics of changes in the value of assets

H

HGGCF

0.050 USD Highway 50 Gold Corp 0 (0%)
Detailed analytics
L

LVH3

0.037 EUR JACKPOT DIGITAL -0 (-1.33%)
Detailed analytics
M

MUE

0.049 EUR 3D OIL -0 (-6.73%)
Detailed analytics
A

AIDA

0.00020 USD Aida Pharmaceuticals Inc 0 (0%)
Detailed analytics
E

E33

0.015 AUD East 33 Ltd 0 (0%)
Detailed analytics